Cohance Lifesciences Announces INR 230 Million Investment in cGMP Oligonucleotide Facility

Cohance Lifesciences Limited, a partner of choice for global innovator pharma companies, announced INR 230 million investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. This strategic investment strengthens Cohance’s integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities. The new facility will enable the Company to take high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics. The facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion, and is designed to meet the stringent requirements of complex oligonucleotide building block production. Customer engagements are already underway, with audits planned in the coming quarters.